Go Deep
Piramal Pharma Limited
Piramal Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 19,537 | -89.4 | 3.42 | 0.70 | 210.12 |
| Sep 2026 | 19,504 | -89.4 | 3.43 | 0.70 | 211.00 |
| Sep 2026 | 19,677 | -87.5 | 3.35 | 0.70 | 206.59 |
| Sep 2026 | 19,677 | -87.5 | 3.35 | 0.70 | 206.59 |
| Sep 2026 | 19,677 | -87.5 | 3.35 | 0.70 | 206.59 |
| Sep 2026 | 19,677 | -87.5 | 3.35 | 0.70 | 206.59 |
| Oct 2026 | 18,878 | -83.9 | 3.21 | 0.70 | 197.97 |
| Oct 2026 | 18,417 | -83.1 | 3.20 | 0.70 | 196.88 |
Piramal Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 22,699,200,000.0 | 27,517,700,000.0 | 21,398,700,000.0 | 19,337,100,000.0 |
| Net Profit | -693,900,000.0 | -88,200,000.0 | -1,361,900,000.0 | -817,000,000.0 |
| EPS | -0.5 | -0.1 | -1.0 | -0.6 |
Piramal Pharma Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 87,588,200,000.0 | 90,610,000,000.0 | 81,064,100,000.0 | 70,324,100,000.0 | — |
| Net Profit | -3,259,400,000.0 | 911,300,000.0 | 178,200,000.0 | -1,864,600,000.0 | — |
| EPS | -2.5 | 0.7 | 0.1 | -1.5 | — |
Piramal Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 179,650,400,000.0 | 156,775,900,000.0 | 153,118,100,000.0 | 145,225,600,000.0 | — |
| Total Liabilities | 98,024,200,000.0 | 75,521,200,000.0 | 74,004,400,000.0 | 77,490,600,000.0 | — |
| Total Equity | 81,625,800,000.0 | 81,254,100,000.0 | 79,113,400,000.0 | 67,735,000,000.0 | — |
Owes vs Owns
Piramal Pharma Limited owed ₹0.55 for every ₹1 it owned in Mar 2026, up from ₹0.53 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.55× | 0.48× | 0.48× | 0.53× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Piramal Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 7.4%Receivables 12.0%Inventory 17.1%Fixed assets (tangible) 31.4%Intangible assets 23.1%Long-term investments 1.4%Other assets 7.7%
How it's funded — Mar 2026
Short-term debt 6.7%Long-term debt 23.9%Payables 13.8%Other liabilities 10.2%Shareholders' equity 45.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,334.8 | 391.9 | 503.5 | 659.6 |
| Receivables | 2,157.7 | 2,349.5 | 2,134.4 | 1,799.3 |
| Inventory | 3,064.4 | 2,312.7 | 2,175.9 | 1,681.4 |
| Fixed assets (tangible) | 5,641.9 | 5,023.5 | 4,816.0 | 4,441.4 |
| Intangible assets | 4,141.9 | 4,086.8 | 4,289.8 | 4,445.7 |
| Long-term investments | 244.2 | 226.8 | 205.3 | 170.1 |
| Other assets | 1,380.1 | 1,286.4 | 1,186.9 | 1,324.9 |
| Liabilities & equity | ||||
| Short-term debt | 1,195.5 | 1,506.2 | 2,075.1 | 2,121.2 |
| Long-term debt | 4,300.0 | 3,214.1 | 2,483.8 | 3,383.5 |
| Payables | 2,479.1 | 1,533.8 | 1,538.4 | 1,192.7 |
| Other liabilities | 1,827.8 | 1,298.1 | 1,303.2 | 1,051.6 |
| Shareholders' equity | 8,162.6 | 8,125.5 | 7,911.4 | 6,773.5 |
| Net tangible assets | 4,020.7 | 4,038.6 | 3,621.6 | 2,327.8 |
Piramal Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 16,525,900,000.0 | 8,923,000,000.0 | 10,045,400,000.0 | 4,838,900,000.0 | — |
| Investing Activities | -8,260,300,000.0 | -4,774,600,000.0 | -4,340,100,000.0 | -13,387,800,000.0 | — |
| Financing Activities | -389,800,000.0 | -4,408,300,000.0 | -4,223,400,000.0 | 8,177,900,000.0 | — |